Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Key Inclusion Criteria:~* Body weight ≥35 kg.~* Subjects must have an eligibleCFTR genotype.~  * Part 1 and Part 3: Heterozygous for F508del and an MF mutation (F/MF)~ * Part 2: Homozygous for F508del (F/F)~* FEV1 value ≥40% and ≤90% of predicted mean for age, sex, and height~Key Exclusion Criteria:~* History of clinically significant cirrhosis with or without portal hypertension.~* Glucose-6-phosphate dehydrogenase (G6PD) deficiency~* Lung infection with organisms associated with a more rapid decline in pulmonary status.~* History of solid organ or hematological transplantation.~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo matched to VX-659/TEZ/IVA in TC treatment period for 4 weeks and placebo matched TEZ/IVA in washout period for 4 days.
- Part 1: VX-659/TEZ/IVA TC - Low Dose (Type: EXPERIMENTAL): Participants received VX-659 80 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
- Part 1: VX-659/TEZ/IVA TC - Medium Dose (Type: EXPERIMENTAL): Participants received VX-659 240 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
- Part 1: VX-659/TEZ/IVA TC - High Dose (Type: EXPERIMENTAL): Participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
- Part 2: TEZ/IVA (Type: ACTIVE_COMPARATOR): Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
- Part 2: VX-659/TEZ/IVA TC (Type: EXPERIMENTAL): Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
- Part 3: Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo matched to VX-659/TEZ/VX-561 in TC treatment period for 4 weeks.
- Part 3: VX-659/TEZ/VX-561 TC (Type: EXPERIMENTAL): Participants received VX-659 400 mg qd/TEZ 100 mg qd/VX-561 200 mg qd in TC treatment period for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).